FuGENE® SI Transfection Reagent

Superior & Gentle siRNA Transfection from the FuGENE^® Brand you Know and Trust

Harnessing the same gentle reliability as our market-leading DNA Transfection Reagents, we are proud to introduce to you FuGENE^® SI, an innovative RNA Transfection reagent engineered for the delivery of siRNA. FuGENE^® SI is a 100% synthetic, multi-component transfection reagent designed for the delivery of RNA molecules into eukaryotic cell lines. FuGENE^® SI allows researchers to obtain maximum efficiency knockdowns while being more gentle on cells than competitor’s reagents. Request a sample today for your RNA delivery needs and See the Unseen^® with FuGENE^® SI.

Benefits of FuGENE^® SI

• High-efficiency transfection of siRNAs into eukaryotic cells
• No cell toxicity or slowing of growth rate
• Superior knockdown efficiencies with lower amounts of siRNAs
• Transfect in serum-free or serum-containing media.
• Save time and effort with our quick protocols and optimizations
• Cost-Effective over competitor reagents

FuGENE® SI POSTER

• Gene Silencing 
• Functional Genomics
• Cellular Analysis
• siRNA library screens
• miRNA delivery
• Short RNA Delivery
  

Human MDA-MB-468 (breast cancer) cells were reverse transfected in 6-well plates with 40 pmol of indicated targeting siRNA and negative/positive controls (Silencer Select®, Life Technologies) with either 7.5ul of FuGENE® SI or 7.5ul of RNAimax® (Life Technologies) per well.  72 hours after transfection the cells were collected and analyzed via western blot for expression of target genes STAT3 and CEBPB. Results demonstrates that FuGENE SI yields robust knockdown of target genes and performs better or comparable to RNAiMax®.

Human MCF-7 cells plated in 6-well microplates were transfected with 10, 20, or 30nM of ARID4B targeting siRNA or negative control (Millipore Sigma, Mission®) utilizing 7.5ul of FuGENE SI per well. 48 hours hours after transfection the cells were collected and 20ug of total cell lysate was analyzed via western blot for expression of target gene ARID4B and control gene HSP70.  Results demonstrate that FuGENE® SI enables robust knockdown of endogenously expressed ARID4B in biologically relevant human cancer cell lines with no unintended off-target effects.

HEK293-GFP & NIH3T3-GFP Cell lines (Cell Biolabs^®) were seeded in 96-well plates according to user guides and subsequently transfected with 0.2, 1.0, or 5 pmols of GFP targeting siRNA or negative control (Horizon Discovery/Dharmacon^®), along with 0.3ul of Transfection Reagent FuGENE^® SI or 0.3ul of Lipofectamine^® RNAiMax (Life Technologies Corporation). Cells were then analyzed via flow cytometry 48 hours post-transfection to measure % knockdown of GFP & total cell viability. Graphs above show the superior knockdown performance of FuGENE^® SI vs. Lipofectamine^® RNAiMax in HEK293 and NIH3T3 cells.